Equities

Beijing Succeeder Technology Inc

688338:SHH

Beijing Succeeder Technology Inc

Actions
Health CareMedical Equipment and Services
  • Price (CNY)23.99
  • Today's Change0.49 / 2.09%
  • Shares traded555.08k
  • 1 Year change-40.40%
  • Beta1.4126
Data delayed at least 15 minutes, as of May 31 2024 08:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Succeeder Technology Inc is a China-based company mainly engaged in the research and development, production and sales of testing instruments, reagents and consumables in the field of thrombosis and hemostasis in vitro diagnosis. The Company provides medical institutions with automated detection equipment for blood coagulation, blood rheology, hematocrit, platelet aggregation, and supporting reagents and consumables. Its products include testing instruments, reagents and consumables, such as automatic coagulation testers, coagulation quality control kits, Newtonian fluid quality controls, reaction cups and SAW blood rheology special cleaning. The Company operates its businesses within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)284.54m
  • Net income in CNY120.76m
  • Incorporated2003
  • Employees296.00
  • Location
    Beijing Succeeder Technology IncTower 1A, No.27 Innovation RoadScience and Technology Park, Changping DBEIJING 102200ChinaCHN
  • Phone+86 1 053855568
  • Fax+86 1 053855570
  • Websitehttp://www.succeeder.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hanshang Group Co Ltd1.36bn49.62m2.45bn2.38k48.741.42--1.800.17070.17074.655.840.37052.758.35573,421.201.162.001.923.8958.3557.243.134.890.33662.150.319815.030.18935.14-32.2425.6212.88--
Jiangsu Cowin Biotech Co Ltd123.20m-117.37m2.48bn657.00--1.52--20.11-1.12-1.121.2114.490.06641.331.23187,520.90-6.63---6.94--58.15---99.82--14.37--0.0184---67.15---153.00------
Zhejiang Cheng Yi Pharmaceutical Co Ltd676.85m155.83m2.50bn738.0015.962.04--3.690.47810.47812.073.740.36661.9211.71917,147.408.4012.0110.1414.7563.8869.7922.9222.841.21--0.258936.442.544.240.812910.94-23.5612.84
Novoprotein Scientific Inc136.28m-927.60k2.52bn579.00--1.15--18.50-0.0132-0.01321.9431.190.05850.44931.67235,364.30-0.0398---0.0409--70.17---0.6807--34.49--0.0353---42.09---85.84------
Ginwa Enterprise Group Inc572.93m-23.61m2.52bn553.00--1.56--4.40-0.0633-0.06331.534.320.29884.745.641,036,046.00-1.230.3641-1.440.414175.6073.64-4.121.153.330.34390.0206124.25-2.41-5.37-228.19--61.66--
Beijing Succeeder Technology Inc284.54m120.76m2.55bn296.0021.091.56--8.951.141.142.6815.360.17112.399.52961,290.607.267.777.638.2562.4861.0342.4338.3414.58--0.0000722.2220.406.6012.2915.5799.03--
Shanghai Fudan Forward S&T Co Ltd665.16m-6.01m2.58bn1.36k--3.24--3.88-0.0089-0.00890.97911.160.37760.60668.47488,010.90-0.3031-0.8781-0.5073-1.5340.8543.22-0.8027-1.850.4956-1.830.3817---13.86-7.58196.17-32.57-13.88--
Cabio Biotech Wuhan Co Ltd473.06m101.38m2.62bn508.0026.231.75--5.540.5940.5942.778.920.29482.492.27931,222.906.017.816.558.3441.3446.9620.4028.656.19--0.00839.862.399.1841.95-1.1989.01--
Jinan High-tech Development Co Ltd555.10m-119.73m2.64bn716.00--13.54--4.75-0.1353-0.13530.62750.22010.18740.61980.6935775,274.40-4.46-2.99-22.92-9.4215.1930.52-23.79-10.840.5687--0.4146---58.29-13.80-618.17---35.45--
Data as of May 31 2024. Currency figures normalised to Beijing Succeeder Technology Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

7.95%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 31 Dec 20231.33m2.10%
China Southern Asset Management Co., Ltd.as of 31 Dec 20231.25m1.96%
Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 2023928.47k1.46%
Gfund Management Co., Ltd.as of 31 Dec 2023379.90k0.60%
Penghua Fund Management Co., Ltd.as of 31 Dec 2023263.84k0.41%
GF Fund Management Co., Ltd.as of 31 Dec 2023233.28k0.37%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023226.49k0.36%
Zheshang Fund Management Co., Ltd.as of 30 Jun 2023196.47k0.31%
Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023176.50k0.28%
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 202375.00k0.12%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.